Evidence map›Paper›PMID 25606684›Full record

ArticleBiophysical journal2015

Small peptide binding stiffens the ubiquitin-like protein SUMO1.

Hema Chandra Kotamarthi, Anju Yadav, Sri Rama Koti Ainavarapu

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 20 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hema Chandra KotamarthiDepartment of Chemical Sciences, Tata Institute of Fundamental Research, Colaba, Mumbai, India.
Anju YadavDepartment of Chemical Sciences, Tata Institute of Fundamental Research, Colaba, Mumbai, India.
Sri Rama Koti AinavarapuDepartment of Chemical Sciences, Tata Institute of Fundamental Research, Colaba, Mumbai, India. Electronic address: koti@tifr.res.in.
Tata Institute of Fundamental Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posttranslational modification by small ubiquitin-like modifiers (SUMOs), known as SUMOylation, is a key regulatory event in many eukaryotic cellular processes in which SUMOs interact with a large number of target proteins. SUMO binding motifs (SBMs) are small peptides derived from these target proteins that interact noncovalently with SUMOs and induce conformational changes. To determine the effect of SBMs on the mechanical properties of SUMO1 (the first member of the human SUMO family), we performed single-molecule force spectroscopy experiments on SUMO1/SBM complexes. The unfolding force of SUMO1 (at a pulling speed of 400 nm/s) increased from ∼ 130 pN to ∼ 170 pN upon binding to SBMs, indicating mechanical stabilization upon complexation. Pulling-speed-dependent experiments and Monte Carlo simulations measured a large decrease in distance to the unfolding transition state for SUMO1 upon SBM binding, which is by far the largest change measured for any ligand binding protein. The stiffness of SUMO1 (measured as a spring constant for the deformation response along the line joining the N- and C-termini) increased upon SBM binding from ∼ 1 N/m to ∼ 3.5 N/m. The relatively higher flexibility of ligand-free SUMO1 might play a role in accessing various conformations before binding to a target.

Indexed as

Molecular Dynamics SimulationAmino Acid SequenceHumansMolecular Sequence DataPeptide FragmentsProtein BindingProtein FoldingProtein Structure, TertiarySUMO-1 ProteinPeptide FragmentsSUMO-1 ProteinSUMO1 protein, human

Identifiers

PMID25606684
PMCPMC4302194
OpenAlexW1997667895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.